Cover Image
Market Research Report
Product code 
953149

Global Next-Generation Breast Cancer Diagnostic and Screening Market: Focus on Products, Technologies, Cancer Sub-Type, End Users, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

Published: | BIS Research Inc. | 206 Pages | Delivery time: 1-2 business days

Price

Back to Top
Global Next-Generation Breast Cancer Diagnostic and Screening Market: Focus on Products, Technologies, Cancer Sub-Type, End Users, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030
Published: August 6, 2020
BIS Research Inc.
Content info: 206 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

"Global Next-Generation Breast Cancer Diagnostics and Screening Market to Reach $10.48 Billion by 2030."

Market Report Coverage - Next Generation Breast Cancer Diagnostic and Screening

Market Segmentation

  • Product Type - BRCA tests, ER/PR tests, HER2 tests
  • Technology- Real-Time Polymerase Chain Reaction (RT-PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), Next-Generation Sequencing and Others
  • Cancer Subtype - Luminal A, Luminal B, Triple negative/basal like, Human Epidermal Growth Factor (HER2)
  • End User - Hospital associated lab, Cancer Research Institutes, Diagnostic Centers, and Other End Users

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, France, Italy, U.K., Spain, and Rest-of-Europe
  • Asia-Pacific - China, Japan, India, Singapore, Australia, and Rest-of-Asia-Pacific (RoAPAC)
  • Latin America - Brazil, Mexico, and Rest-of-the-Latin America
  • Rest-of-the-World

Growth Drivers

  • Increasing Prevalence of Breast Cancer, Globally
  • Increase in Adoption of Personalized Medicine for the Screening and Diagnostics of Breast Cancer
  • Growing Focus on Breast Cancer Biomarker for Effective Screening and Prognosis

Market Challenges

  • Uncertain Reimbursement Policies Pertaining to Breast Cancer Molecular Diagnostics
  • Requirement of High Capital Investment Hindering Expansion
  • Issues Related to Clinical Validity of Biomarker-based Tests

Market Opportunities

  • Massive Scope for Adoption of Breast Cancer Molecular Diagnostics in Emerging Nations
  • Technological Advancements in the development of Next Generation Breast Cancer Diagnostics
  • Increased Use of Breast Cancer Diagnostics for the Development of Therapeutics Drugs and Comprehensive Treatment Plan

Key Companies Profiled

Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, Invitae Corporation, Thermo Fisher Scientific Inc., Biocept, Inc., Biotheranostics, Agendia N.V., Lucence Diagnostics Pte Ltd, Agilent Technologies, Inc., Myriad Genetics, Inc, Fulgent Genetics, Centogene N.V., and Ambry Genetics

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities in the next generation breast cancer diagnosis and screening market?
  • What is the potential impact of COVID-19 on the breast cancer diagnosis in terms of availability of resources such as physicians, laboratory staff and technological advancements?
  • What are the noticeable drifts across various regional markets amidst the COVID-19 pandemic on the early stage screening of breast cancer?
  • What is the current market demand along with future expected demand trend of Next generation breast cancer diagnostics services for various subtypes.?
  • How the next generation diagnostics have helped genomic tests to become a prominent tool for breast cancer screening rather than an adjunct diagnostic tool?
  • What are the key development strategies which are implemented by the major players in order to sustain in the competitive market?
  • What are the key technologies that have been used by leading players in the market for the development of molecular diagnostic assays for early breast cancer screening and diagnosis?
  • How each segment of the market is expected to grow during the forecast period from 2020 to 2030 based on:
    • Technology
    • Assay Type
    • Breast Cancer Subtypes
    • Diagnostic Type
    • End user
    • Region: Region includes North America, Europe, Asia-Pacific, Rest-of-the-World (ROW)
  • Who are the leading players with significant offerings to the next generation breast cancer diagnosis and screening market? What is the expected market dominance for each of these leading players?
  • Which companies are anticipated to be highly disruptive in the future and why?

Market Overview

Our healthcare experts have found next generation breast cancer diagnostics and screening market to be one of the most rapidly evolving markets and the global market for next generation breast cancer diagnostics and screening market is predicted to grow at a CAGR of 13.12% over the forecast period of 2020-2030. The market is driven by certain factors, which include the rising incidence of breast cancer patients inciting the development of rapid diagnostic assays, significant innovation resulting in market pull, shift from centralized to decentralized laboratories, and significant external funding for executing R&D exercises.

The market is favoured by the development of genomic-based assays for early diagnosis and prognosis of metastatic and recurrent breast cancers. The gradual increase in the prevalence of breast cancer patients, globally has furthered the breast cancer diagnostics market.

Furthermore, several diagnostic companies are focusing on the development of biomarker-diagnostics with higher sensitivity and low turn-around time to benefit the patients, providing diagnosis at an early stage.

Within the research report, the market is segmented on the basis of product type, application, technology, disease end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of precision medicine on the global level has created a buzz among companies to invest in the development of rapid diagnostics providing information on genetic mutation and patients good candidate for adjuvant chemotherapy or hormonal therapy. Due to the diverse product portfolio and intense market penetration, Abbott Laboratories has been a pioneer in this field and been a significant competitor in this market.

Several other companies such as F. Hoffman-La Roche Ltd, Myriad Genetics Inc., and Agendia, among others, have launched diagnostics assays for breast cancer, such as Foundation One CDx, EndoPredict, and Mammaprint, among others.

On the basis of region, North America holds the largest share of next generation breast cancer diagnostics and screening market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

Table of Contents
Product Code: BHP0940SA

Table of Contents

Executive Summary.

1. Product Definition

  • 1.1. Definition by Products
    • 1.1.1. Assays
  • 1.2. Inclusion and Exclusion

2. Market Scope

  • 2.1. Scope of Work
  • 2.2. Key Questions Answered in the Report

3. Research Methodology

  • 3.1. Primary Data Sources
  • 3.2. Secondary Data Sources
  • 3.3. Market Estimation Model

4. Market Overview

  • 4.1. Introduction
  • 4.2. Implementation of Precision Medicine in Breast Cancer Diagnostics
  • 4.3. Impact of COVID-19 on Delivery of Care for Cancer Patients
  • 4.4. Breast Cancer Clinical Trials

5. Next-Generation Breast Cancer Diagnostics and Screening Market Dynamics

  • 5.1. Overview
  • 5.2. Impact Analysis
  • 5.3. Market Drivers
    • 5.3.1. Increasing Prevalence of Breast Cancer Globally
    • 5.3.2. Increasing Adoption of Personalized Medicine for Screening and Diagnostics of Breast Cancer
    • 5.3.3. Growing Focus on Breast Cancer Biomarker for Effective Screening and Prognosis
  • 5.4. Market Restraints
    • 5.4.1. Uncertain Reimbursement Policies Pertaining to Breast Cancer Molecular Diagnostics
    • 5.4.2. Unavailability of High Capital Investment Hindering Expansion
    • 5.4.3. Issues Related to Clinical Validity of Biomarker-Based Tests
  • 5.5. Market Opportunities
    • 5.5.1. Massive Scope for Adoption of Breast Cancer Molecular Diagnostics in Emerging Nations
    • 5.5.2. Technological Advancements in the Development of Next-Generation Breast Cancer Diagnostics
    • 5.5.3. Increased Use of Breast Cancer Diagnostics for the Development of Therapeutics Drugs and Comprehensive Treatment Plan

6. Competitive Landscape

  • 6.1. Key Strategies and Developments
    • 6.1.1. Product Approvals
    • 6.1.2. Product Launches and Upgradations
    • 6.1.3. Synergistic Activities
    • 6.1.4. Funding and Expansion
    • 6.1.5. Mergers and Acquisitions
    • 6.1.6. Other
  • 6.2. Market Share Analysis (by Company), 2019
  • 6.3. Growth Share Analysis (Opportunity Mapping)
    • 6.3.1. By Company

7. Next-Generation Breast Cancer Diagnostics and Screening Market (by Technology), 2019-2030

  • 7.1. Overview
  • 7.2. Real-Time PCR (q-PCR)
  • 7.3. Immunohistochemistry (IHC)
  • 7.4. Next-Generation Sequencing (NGS)
  • 7.5. Fluorescent In-Situ Hybridization (FISH)
  • 7.6. Other

8. Next-Generation Breast Cancer Diagnostics and Screening Market (by Cancer Subtype) 2019-2030

  • 8.1. Overview
  • 8.2. Luminal A
  • 8.3. Luminal B
  • 8.4. Triple-Negative/Basal-Like
  • 8.5. Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched

9. Next-Generation Breast Cancer Diagnostics and Screening Market (by Test Type) 2019-2030

  • 9.1. Overview
  • 9.2. BRCA Test
  • 9.3. ER/PR Receptors
  • 9.4. HER-2 Tests
  • 9.5. Other

10. Next-Generation Breast Cancer Diagnostic and Screening Market (by Region) 2019-2030

  • 10.1. Overview
  • 10.2. North America
    • 10.2.1. U.S.
    • 10.2.2. Canada
  • 10.3. Europe
    • 10.3.1. Germany
    • 10.3.2. U.K.
    • 10.3.3. France
    • 10.3.4. Italy
    • 10.3.5. Spain
    • 10.3.6. Rest-of-Europe
  • 10.4. Asia-Pacific
    • 10.4.1. China
    • 10.4.2. Japan
    • 10.4.3. India
    • 10.4.4. Australia
    • 10.4.5. Singapore
    • 10.4.6. Rest-of-APAC
  • 10.5. Latin America
    • 10.5.1. Brazil
    • 10.5.2. Mexico
    • 10.5.3. Rest-of-Latin America
  • 10.6. Rest-of-the-World

11. Next-Generation Breast Cancer Diagnostics and Screening Market (by End User), 2019-2030

  • 11.1. Overview
  • 11.2. Hospital-associated Labs
  • 11.3. Cancer Research Institutes
  • 11.4. Diagnostic Centers
  • 11.5. Other End Users

12. Company Profiles

  • 12.1. Overview
  • 12.2. Abbott Laboratories
    • 12.2.1. Company Overview
    • 12.2.2. Role of Abbott Laboratories in the Next-Generation Breast Cancer Diagnostic and Screening Market
    • 12.2.3. Financials
      • 12.2.3.1. Key Insights About Financial Health of the Company
    • 12.2.4. SWOT Analysis
  • 12.3. Agendia
    • 12.3.1. Company Overview
    • 12.3.2. Role of Agendia in Next-Generation Breast Cancer Diagnostic and Screening Market
    • 12.3.3. SWOT Analysis
  • 12.4. Agilent Technologies, Inc.
    • 12.4.1. Company Overview
    • 12.4.2. Role of Agilent Technologies, Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
    • 12.4.3. Financials
      • 12.4.3.1. Key Insights About Financial Health of the Company
    • 12.4.4. SWOT Analysis
  • 12.5. Ambry Genetics
    • 12.5.1. Company Overview
    • 12.5.2. Role of the Ambry Genetics in the Next-Generation Diagnostic and Screening Market
    • 12.5.3. SWOT Analysis
  • 12.6. Biocept, Inc.
    • 12.6.1. Company Overview
    • 12.6.2. Role of Biocept, Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
    • 12.6.3. Financials
      • 12.6.3.1. Key Insights About Financial Health of the Company
    • 12.6.4. SWOT Analysis
  • 12.7. Biotheranostics, Inc.
    • 12.7.1. Company Overview
    • 12.7.2. Role of the Biotheranostics, Inc. in the Next-Generation Diagnostic and Screening Market
    • 12.7.3. SWOT Analysis
  • 12.8. CENTOGENE N.V.
    • 12.8.1. Company Overview
    • 12.8.2. Role of CENTOGENE N.V. in the Next-Generation Breast Cancer Diagnostic and Screening Market
    • 12.8.3. Financials
      • 12.8.3.1. Key Insights About Financial Health of the Company
    • 12.8.4. SWOT Analysis
  • 12.9. Danaher Corporation
    • 12.9.1. Company Overview
    • 12.9.2. Role of Danaher Corporation in the Next-Generation Breast Cancer Diagnostic and Screening Market
    • 12.9.3. Financials
      • 12.9.3.1. Key Insights About Financial Health of the Company
    • 12.9.4. SWOT Analysis
  • 12.1. Exact Sciences Corporation
    • 12.10.1. Company Overview
    • 12.10.2. Role of Exact Sciences Corporation in the Next-Generation Breast Cancer Diagnostic and Screening Market
    • 12.10.3. Financials
      • 12.10.3.1. Key Insights About Financial Health of the Company
    • 12.10.4. SWOT Analysis
  • 12.11. F. Hoffmann-La Roche Ltd.
    • 12.11.1. Company Overview
    • 12.11.2. Role of F. Hoffmann-La Roche Ltd. in the Next-Generation Breast Cancer Diagnostic and Screening Market
    • 12.11.3. Financials
      • 12.11.3.1. Key Insights About Financial Health of the Company
    • 12.11.4. SWOT Analysis
  • 12.12. Fulgent Genetics
    • 12.12.1. Company Overview
    • 12.12.2. Role of Fulgent Genetics in the Next-Generation Breast Cancer Diagnostic and Screening Market
    • 12.12.3. Financials
      • 12.12.3.1. Key Insights About Financial Health of the Company
    • 12.12.4. SWOT Analysis
  • 12.13. Illumina, Inc.
    • 12.13.1. Company Overview
    • 12.13.2. Role of Illumina, Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
    • 12.13.3. Financials
      • 12.13.3.1. Key Insights about Financial Health of the Company
    • 12.13.4. SWOT Analysis
  • 12.14. Invitae Corporation
    • 12.14.1. Company Overview
    • 12.14.2. Role of Invitae Corporation, Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
    • 12.14.3. Financials
      • 12.14.3.1. Key Insights About Financial Health of the Company
    • 12.14.4. SWOT Analysis
  • 12.15. Lucence Diagnostics Pte Ltd
    • 12.15.1. Company Overview
    • 12.15.2. Role of the Lucene Diagnostic Pte Ltd in Next-Generation Breast Cancer Diagnostic and Screening Market
    • 12.15.3. SWOT Analysis
  • 12.16. Myriad Genetics, Inc.
    • 12.16.1. Company Overview
    • 12.16.2. Role of Myriad Genetics, Inc. in the Next-Generation Breast Cancer Diagnostic Market
    • 12.16.3. Financials
      • 12.16.3.1. Key Insights About Financial Health of the Company
    • 12.16.4. SWOT Analysis

List of Tables

  • Table 4.1: Breast Cancer Clinical Trials
  • Table 5.1: Likert Scale
  • Table 5.2: Impact Analysis of Market Drivers
  • Table 5.3: Impact Analysis of Market Restraints
  • Table 7.1: Key Products Offered Based on RT-PCR
  • Table 7.2: Key Products Offered Based on IHC
  • Table 7.3: Key Products Offered Based on NGS
  • Table 7.4: Key Products Offered Based on FISH
  • Table 7.5: Key Products Offered Based on Other Technology
  • Table 9.1: Key Products Offered Based on BRCA Test
  • Table 9.2: Key Products Offered Based on ER/PR Test
  • Table 9.3: Key Products Offered Based on HER-2

List of Figures

  • Figure 1: Worldwide Breast Cancer Statistics (by Region), 2018
  • Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Next-Generation Breast Cancer Diagnostics and Screening Market
  • Figure 3: Next-Generation Breast Cancer Diagnostics and Screening Market (by Product Type), ($Million), 2020 vs 2030
  • Figure 4: Next-Generation Breast Cancer Diagnostics and Screening Market (by Technology), ($Million), 2020 vs. 2030
  • Figure 5: Next-GenerationNext-Generation Breast Cancer Diagnostic and Screening Market (by Cancer Subtype), ($Million), 2020 vs. 2030
  • Figure 6: Next-Generation Breast Cancer Diagnostics and Screening Market (by End User), ($Million), 2020 vs. 2030
  • Figure 7: Next-Generation Breast Cancer Diagnostics and Screening Market Snapshot
  • Figure 2.1: Next-Generation Breast Cancer Diagnostics and Screening Segmentation
  • Figure 3.1: Primary Research Methodology
  • Figure 3.2: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.3: Top-Down Approach (Segment-Wise Analysis)
  • Figure 5.1: Number of Cases (in Million) by Different Forms of Cancer, 2018
  • Figure 5.2: Global Incidence of Breast Cancer Cases, As of 2018
  • Figure 6.1: Share of Key Developments and Strategies, 2017-2020
  • Figure 6.2: Product Approval Share (by Company), 2017-2020
  • Figure 6.3: Product Launch and Upgradation Share (by Company), 2017-2020
  • Figure 6.4: Synergistic Activities Share (by Company), 2017-2020
  • Figure 6.5: Funding and Expansion Share (by Company), 2017-2020
  • Figure 6.6: Mergers and Acquisitions Share (by Company), 2017-2020
  • Figure 6.7: Other Key Development Share (by Company), 2017-2020
  • Figure 6.8: Market Share Analysis for the Next-Generation Breast Cancer Diagnostics and Screening Market, 2019
  • Figure 6.9: Growth Share Matrix for Next-Generation Breast Cancer Diagnostics and Screening (by Company), 2019
  • Figure 7.1: Next-Generation Breast Cancer Diagnostics and Screening Market (by Technology), ($Million), 2019-2030
  • Figure 7.2: Global Next-Generation Breast Cancer Diagnostics and Screening Market (RT-PCR), ($Million), 2019-2030
  • Figure 7.3: Global Next-Generation Breast Cancer Diagnostics and Screening Market (IHC), ($Million), 2019-2030
  • Figure 7.4: Global Next-Generation Breast Cancer Diagnostics and Screening Market (NGS), ($Million), 2019-2030
  • Figure 7.5: Global Next-Generation Breast Cancer Diagnostics and Screening Market (FISH), (($Million)), 2019-2030
  • Figure 7.6: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Other), 2019-2030 ($ Million)
  • Figure 8.1: Next-Generation Breast Cancer Diagnostic and Screening Market (by Cancer Subtype), ($Million), 2019-2030
  • Figure 8.2: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Luminal A), ($Million), 2019-2030
  • Figure 8.3: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Luminal B), ($Million), 2019-2030
  • Figure 8.4: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Triple-negative/basal-like), ($Million), 2019-2030
  • Figure 8.5: Global Next-Generation Breast Cancer Diagnostics and Screening Market (by HER-2 Enriched), ($Million), 2019-2030
  • Figure 9.1: Next-Generation Breast Cancer Diagnostic and Screening Market (by Test Type),($Million), 2019-2030
  • Figure 9.2: Global Next-Generation Breast Cancer Diagnostics and Screening Market (BRCA), ($Million), 2019-2030
  • Figure 9.3: Global Next-Generation Breast Cancer Diagnostics and Screening Market (ER/PR Receptor), ($Million), 2019-2030
  • Figure 9.4: Global Next-Generation Breast Cancer Diagnostics and Screening Market (HER-2), ($Million), 2019-2030
  • Figure 9.5: Global Next-Generation Breast Cancer Diagnostics and Screening Market (by Other), ($Million), 2019-2030
  • Figure 10.1: Next-Generation Breast Cancer Diagnostic and Screening Market (by Region), ($Million), 2020 and 2030
  • Figure 10.2: Next-Generation Breast Cancer Diagnostic and Screening Market (by Region), ($Million), 2019-2030
  • Figure 10.3: North America Next-Generation Breast Cancer Diagnostic and Screening Market, (($Million)), 2019-2030
  • Figure 10.4: North America Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), ($Million), 2019-2030
  • Figure 10.5: North America: Market Dynamics
  • Figure 10.6: U.S. Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030
  • Figure 10.7: Canada Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030
  • Figure 10.8: Europe Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
  • Figure 10.9: Europe: Market Dynamics
  • Figure 10.10: Europe Next-Generation Breast Cancer Diagnostics and Screening Market (by Country), ($Million), 2019-2030
  • Figure 10.11: Germany Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
  • Figure 10.12: U.K. Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
  • Figure 10.13: France Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
  • Figure 10.14: Italy Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
  • Figure 10.15: Spain Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
  • Figure 10.16: Rest-of-Europe Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
  • Figure 10.17: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030,
  • Figure 10.18: APAC: Market Dynamics
  • Figure 10.19: APAC Global Next-Generation Breast Cancer Diagnostics and Screening Market (by Country), ($Million), 2019-2030
  • Figure 10.20: China Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
  • Figure 10.21: Japan Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
  • Figure 10.22: India Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
  • Figure 10.23: Australia Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
  • Figure 10.24: Singapore Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
  • Figure 10.25: RoAPAC Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
  • Figure 10.26: Latin America Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030
  • Figure 10.27: Latin America: Market Dynamics
  • Figure 10.28: Latin America Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), ($Million), 2019-2030
  • Figure 10.29: Brazil Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million) 2019-2030,
  • Figure 10.30: Mexico Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030,
  • Figure 10.31: Rest-of-Latin America Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million) 2019-2030
  • Figure 10.32: RoW Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030,
  • Figure 11.1: Next-Generation Breast Cancer Diagnostic and Screening Market (by End User), ($Million), 2019-2030
  • Figure 11.2: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Hospital-associated labs), 2019-2030 ($ Million)
  • Figure 11.3: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Cancer Research Institutes), ($Million), 2019-2030
  • Figure 11.4: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Diagnostic Centers), ($Million), 2019-2030
  • Figure 11.5: Global Next-Generation Breast Cancer Diagnostics and Screening Market (by Other End Users), 2019-2030
  • Figure 12.1: Total Number of Companies Profiled
  • Figure 12.2: Abbott Laboratories: Portfolio
  • Figure 12.3: Abbott Laboratories: Overall Financials, 2017-2019
  • Figure 12.4: Abbott Laboratories: Revenue (by Segment), 2017-2019
  • Figure 12.5: Abbott Laboratories: Revenue Split for Diagnostics, 2017-2019
  • Figure 12.6: Abbott Laboratories: Revenue (by Region), 2017-2019
  • Figure 12.7: Abbott Laboratories: R&D Expenditure, 2017-2019
  • Figure 12.8: Abbott Laboratories: SWOT Analysis
  • Figure 12.9: Agendia: Product Portfolio
  • Figure 12.10: Agendia: SWOT Analysis
  • Figure 12.11: Agilent Technologies, Inc.: Overall Product Portfolio
  • Figure 12.12: Agilent Technologies, Inc.: Overall Financials, 2017-2019
  • Figure 12.13: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
  • Figure 12.14: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
  • Figure 12.15: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
  • Figure 12.16: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 12.17: Ambry Genetics: Product portfolio
  • Figure 12.18: Ambry Genetics: SWOT Analysis
  • Figure 12.19: Biocept, Inc.: Portfolio
  • Figure 12.20: Biocept, Inc.: Overall Financials, 2017-2019
  • Figure 12.21: Biocept, Inc.: Sales (by Segment), 2017-2019
  • Figure 12.22: Biocept, Inc.: R&D Expenditure, 2017-2019
  • Figure 12.23: Biocept, Inc.: SWOT Analysis
  • Figure 12.24: Biotheranostics, Inc.: Product Portfolio
  • Figure 12.25: Biotheranostics, Inc.: SWOT Analysis
  • Figure 12.26: CENTOGENE N.V.: Overall Product Portfolio
  • Figure 12.27: CENTOGENE N.V.: Overall Financials, 2017-2019
  • Figure 12.28: CENTOGENE N.V.: Sales (by Segment), 2016-2018
  • Figure 12.29: CENTOGENE N.V.: Sales (by Region), 2017-2019
  • Figure 12.30: CENTOGENE N.V.: R&D Expenditure, 2017-2019
  • Figure 12.31: CENTOGENE N.V.: SWOT Analysis
  • Figure 12.32: Danaher Corporation: Product Portfolio
  • Figure 12.33: Danaher Corporation: Overall Financials, 2017-2019
  • Figure 12.34: Danaher Corporation: Revenue (by Business Segment), 2017-2019
  • Figure 12.35: Danaher Corporation: Revenue (by Region), 2017-2019
  • Figure 12.36: Danaher Corporation: R&D Expenditure, 2016-2018
  • Figure 12.37: Danaher Corporation: SWOT Analysis
  • Figure 12.38: Exact Science Corporation: Product Portfolio
  • Figure 12.39: Exact Sciences Corporation: Overall Financials, 2017-2019
  • Figure 12.40: Exact Sciences Corporation: Revenue (by Business Segment), 2017-2019
  • Figure 12.41: Exact Sciences Corporation: Revenue (by Region), 2017-2019
  • Figure 12.42: Exact Sciences Corporation: R&D Expenditure, 2017-2019
  • Figure 12.43: Exact Sciences Corporation: SWOT Analysis
  • Figure 12.44: F. Hoffmann-La Roche Ltd.: Portfolio
  • Figure 12.45: F. Hoffmann-La Roche Ltd.: Overall Financials, 2017-2019
  • Figure 12.46: F. Hoffmann-La Roche Ltd.: Sales (by Segment), 2017-2019
  • Figure 12.47: F. Hoffmann-La Roche Ltd: Sales (by Region), 2017-2019
  • Figure 12.48: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2017-2019
  • Figure 12.49: F. Hoffmann-La Roche Ltd.: SWOT Analysis
  • Figure 12.50: Fulgent Genetics: Product Portfolio
  • Figure 12.51: Fulgent Genetics: Overall Financials, 2017-2019
  • Figure 12.52: Fulgent Genetics: Revenue (by Business Segment), 2018-2019
  • Figure 12.53: Fulgent Genetics: Revenue (by Region), 2017-2019
  • Figure 12.54: Fulgent Genetics: R&D Expenditure, 2017-2019
  • Figure 12.55: Fulgent Genetics: SWOT Analysis
  • Figure 12.56: Illumina, Inc.: Portfolio
  • Figure 12.57: Illumina, Inc.: Overall Financials, 2017-2019
  • Figure 12.58: Illumina, Inc.: Revenue (by Segment), 2017-2019
  • Figure 12.59: Illumina, Inc.: Revenue (by Region), 2017-2019
  • Figure 12.60: Illumina, Inc.: R&D Expenditure, 2017-2019
  • Figure 12.61: Illumina, Inc.: SWOT Analysis
  • Figure 12.62: Invitae Corporation: Overall Product Portfolio
  • Figure 12.63: Invitae Corporation: Overall Financials, 2017-2019
  • Figure 12.64: Invitae Corporation: Revenue (by Segment), 2017-2019
  • Figure 12.65: Invitae Corporation: Revenue (by Geography), 2017-2019
  • Figure 12.66: Invitae Corporation: R&D Expenditure, 2017-2019
  • Figure 12.67: Invitae Corporation: SWOT Analysis
  • Figure 12.68: Lucene Diagnostics Pte Ltd: Product Portfolio
  • Figure 12.69: Lucene Diagnostic Pte Ltd: SWOT Analysis
  • Figure 12.70: Myriad Genetics, Inc.: Overall Product Portfolio
  • Figure 12.71: Myriad Genetics, Inc.: Overall Financials, 2017-2019
  • Figure 12.72: Myriad Genetics, Inc.: Revenue (by Business Segment), 2017-2019
  • Figure 12.73: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
  • Figure 12.74: Myriad Genetics, Inc.: SWOT Analysis